Compare Sun Pharma with AANJANEYA LIFECARE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs DR. DATSONS LABS - Comparison Results

SUN PHARMA     Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA DR. DATSONS LABS SUN PHARMA/
DR. DATSONS LABS
 
P/E (TTM) x 27.0 -10.9 - View Chart
P/BV x 2.3 0.2 1,436.8% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 SUN PHARMA   DR. DATSONS LABS
EQUITY SHARE DATA
    SUN PHARMA
Mar-19
DR. DATSONS LABS
Mar-14
SUN PHARMA/
DR. DATSONS LABS
5-Yr Chart
Click to enlarge
High Rs679126 540.4%   
Low Rs37531 1,214.9%   
Sales per share (Unadj.) Rs121.1133.0 91.1%  
Earnings per share (Unadj.) Rs13.40.2 8,822.8%  
Cash flow per share (Unadj.) Rs20.76.6 313.0%  
Dividends per share (Unadj.) Rs2.750-  
Dividend yield (eoy) %0.50-  
Book value per share (Unadj.) Rs172.6128.8 134.0%  
Shares outstanding (eoy) m2,399.2631.66 7,578.2%   
Bonus/Rights/Conversions -FCCB-  
Price / Sales ratio x4.40.6 739.5%   
Avg P/E ratio x39.4516.1 7.6%  
P/CF ratio (eoy) x25.511.8 215.2%  
Price / Book Value ratio x3.10.6 502.7%  
Dividend payout %20.60-   
Avg Mkt Cap Rs m1,264,6502,477 51,047.6%   
No. of employees `00017.5NA-   
Total wages/salary Rs m59,67156 106,555.2%   
Avg. sales/employee Rs Th16,608.1NM-  
Avg. wages/employee Rs Th3,409.6NM-  
Avg. net profit/employee Rs Th1,833.8NM-  
INCOME DATA
Net Sales Rs m290,6594,211 6,903.2%  
Other income Rs m10,25579 13,030.4%   
Total revenues Rs m300,9144,289 7,015.6%   
Gross profit Rs m63,076569 11,093.2%  
Depreciation Rs m17,533204 8,577.5%   
Interest Rs m5,553430 1,290.7%   
Profit before tax Rs m50,24613 395,636.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-2 0.0%   
Extraordinary Inc (Exp) Rs m-12,1440-   
Tax Rs m6,0096 98,504.9%   
Profit after tax Rs m32,0935 668,608.3%  
Gross profit margin %21.713.5 160.7%  
Effective tax rate %12.048.0 24.9%   
Net profit margin %11.00.1 9,685.5%  
BALANCE SHEET DATA
Current assets Rs m310,6926,852 4,534.6%   
Current liabilities Rs m173,3966,711 2,583.9%   
Net working cap to sales %47.23.3 1,410.5%  
Current ratio x1.81.0 175.5%  
Inventory Days Days99161 61.6%  
Debtors Days Days112318 35.0%  
Net fixed assets Rs m232,4773,673 6,329.3%   
Share capital Rs m2,399317 757.8%   
"Free" reserves Rs m411,6913,761 10,946.3%   
Net worth Rs m414,0914,078 10,155.5%   
Long term debt Rs m15,2261,671 911.3%   
Total assets Rs m646,93812,633 5,121.2%  
Interest coverage x10.01.0 976.1%   
Debt to equity ratio x00.4 9.0%  
Sales to assets ratio x0.40.3 134.8%   
Return on assets %5.83.4 169.0%  
Return on equity %7.80.1 6,583.7%  
Return on capital %10.27.7 132.5%  
Exports to sales %022.9 0.0%   
Imports to sales %014.3 0.0%   
Exports (fob) Rs mNA964 0.0%   
Imports (cif) Rs mNA602 0.0%   
Fx inflow Rs m66,025964 6,849.1%   
Fx outflow Rs m38,610607 6,359.8%   
Net fx Rs m27,415357 7,681.5%   
CASH FLOW
From Operations Rs m21,9651,345 1,633.3%  
From Investments Rs m-6,813-2,256 302.0%  
From Financial Activity Rs m-27,305-1,200 2,275.8%  
Net Cashflow Rs m-8,442-2,111 399.9%  

Share Holding

Indian Promoters % 63.7 4.5 1,406.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.1 0.0 -  
FIIs % 23.0 1.4 1,703.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 94.1 8.8%  
Shareholders   133,026 20,807 639.3%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  UNICHEM LAB  ALKEM LABORATORIES  PROCTER & GAMBLE HEALTH  

Compare SUN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 265.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUN PHARMA has posted a net profit of Rs 15 bn (up 265.5% YoY). Sales on the other hand came in at Rs 77 bn (up 16.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 20, 2018 | Updated on Dec 20, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Oct 18, 2019 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA 8-QTR ANALYSIS

COMPARE SUN PHARMA WITH

MARKET STATS